MedTrace Logo

Quality Control of CE-Certified Phonak Hearing Aids - 2017_13

NCT03131557 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-08-17

No results posted yet for this study

Summary

A methodical evaluation of new CE-labelled Phonak Hearing Systems is intended to be conducted on hard of participants with a hearing loss to grant quality control prior to product launch. The aim of the investigation series is to ensure usability, zero-defect overall performance of the new hearing systems as well as maximum benefit for the participant with the devices in comparison to previously outstanding Phonak Hearing Systems.

Conditions

  • Hearing Loss, Bilateral Sensorineural, Progressive

Interventions

DEVICE

Line extension of the Phonak Audéo B product family

The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.

DEVICE

Phonak Audéo B

Phonak Audéo B will be fitted to the participants individual hearing loss.

Sponsors & Collaborators

  • Sonova AG

    lead INDUSTRY

Principal Investigators

  • Simone Ebbing, B.Sc. · Sonova AG

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-12
Primary Completion
2017-07-18
Completion
2017-07-18

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03131557 on ClinicalTrials.gov